ID   IRNE
AC   CVCL_C263
SY   IRNE-MEL; BB74-MEL
DR   cancercelllines; CVCL_C263
DR   Cosmic; 972261
DR   Cosmic; 2163787
DR   Cosmic; 2759412
DR   ESTDAB; ESTDAB-038
DR   Wikidata; Q54898254
RX   PubMed=9894850;
RX   PubMed=15592718;
RX   PubMed=19340423;
RX   PubMed=23472218;
RX   PubMed=23493799;
RX   PubMed=23851445;
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   HLA typing: A*01:01,29:02; B*35:01,44:03:01; C*04:01:01; DPB1*04:02,02:01:02; DQB1*06:03,02:01; DRB1*11:03:01,07:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
CC   Discontinued: ESTDAB; ESTDAB-038; probable.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 18
//
RX   PubMed=9894850; DOI=10.1111/j.1399-0039.1998.tb03082.x;
RA   Benitez R., Godelaine D., Lopez-Nevot M.A., Brasseur F., Jimenez P.,
RA   Marchand M., Oliva M.R., van Baren N., Cabrera T., Andry G.,
RA   Landry C., Ruiz-Cabello Osuna F., Boon T., Garrido F.;
RT   "Mutations of the beta2-microglobulin gene result in a lack of HLA
RT   class I molecules on melanoma cells of two patients immunized with
RT   MAGE peptides.";
RL   Tissue Antigens 52:520-529(1998).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23472218; DOI=10.1371/journal.pone.0058743; PMCID=PMC3589373;
RA   Cannuyer J., Loriot A., Parvizi G.K., De Smet C.;
RT   "Epigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter
RT   DNA methylation dictates local histone modifications.";
RL   PLoS ONE 8:E58743-E58743(2013).
//
RX   PubMed=23493799; DOI=10.3389/fimmu.2013.00062; PMCID=PMC3595569;
RA   Pich-Bavastro C., Teiti I., Rochaix P., Mariame B., Couderc B., Favre G.,
RA   Tilkin-Mariame A.-F.;
RT   "Statins reduce melanoma development and metastasis through MICA
RT   overexpression.";
RL   Front. Immunol. 4:62.1-62.11(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//